Literature DB >> 14719804

Aza-peptide epoxides: potent and selective inhibitors of Schistosoma mansoni and pig kidney legumains (asparaginyl endopeptidases).

Karen Ellis James1, Marion G Götz, Conor R Caffrey, Elizabeth Hansell, Wendy Carter, Alan J Barrett, James H McKerrow, James C Powers.   

Abstract

Aza-peptide epoxides are a new class of irreversible cysteine protease inhibitors. Derivatives containing a P1 aza-asparagine residue are specific for Schistosoma mansoni and pig kidney legumains, which are clan CD cysteine proteases. The inhibitors have second-order rate constants of up to 10(4) M(-1) s(-1) with pig kidney legumain and IC50 values as low as 45 nM with S. mansoni legumain. The most potent epoxides contain an ester moiety with S,S stereochemistry attached to the epoxide. Interestingly, amide and amino acid derivatives of the epoxysuccinate moiety were not inhibitors of legumain, while disubstituted amide derivatives are quite potent. The inhibitors have little or no inhibitory activity with other proteases such as caspases, chymotrypsin, papain, cathepsin B, granzyme B, and various aspartyl proteases.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14719804     DOI: 10.1515/BC.2003.179

Source DB:  PubMed          Journal:  Biol Chem        ISSN: 1431-6730            Impact factor:   3.915


  9 in total

1.  Synthesis and evaluation of aza-peptidyl inhibitors of the lysosomal asparaginyl endopeptidase, legumain.

Authors:  Jiyoun Lee; Matthew Bogyo
Journal:  Bioorg Med Chem Lett       Date:  2011-12-21       Impact factor: 2.823

2.  Counter Selection Substrate Library Strategy for Developing Specific Protease Substrates and Probes.

Authors:  Marcin Poreba; Rigmor Solberg; Wioletta Rut; Ngoc Nguyen Lunde; Paulina Kasperkiewicz; Scott J Snipas; Marko Mihelic; Dusan Turk; Boris Turk; Guy S Salvesen; Marcin Drag
Journal:  Cell Chem Biol       Date:  2016-07-28       Impact factor: 8.116

3.  Effects of legumain as a potential prognostic factor on gastric cancers.

Authors:  Na Li; Qiaoling Liu; Qi Su; Chongyang Wei; Bin Lan; Jianyong Wang; Guoqing Bao; Fei Yan; Ying Yu; Baowei Peng; Ju Qiu; Xiangming Yan; Sheng Zhang; Fang Guo
Journal:  Med Oncol       Date:  2013-06-06       Impact factor: 3.064

4.  The legumain protease-activated auristatin prodrugs suppress tumor growth and metastasis without toxicity.

Authors:  Krishna Mohan Bajjuri; Yuan Liu; Cheng Liu; Subhash C Sinha
Journal:  ChemMedChem       Date:  2011-01-03       Impact factor: 3.466

5.  Development of near-infrared fluorophore (NIRF)-labeled activity-based probes for in vivo imaging of legumain.

Authors:  Jiyoun Lee; Matthew Bogyo
Journal:  ACS Chem Biol       Date:  2010-02-19       Impact factor: 5.100

6.  Crystal structures reveal an induced-fit binding of a substrate-like Aza-peptide epoxide to SARS coronavirus main peptidase.

Authors:  Ting-Wai Lee; Maia M Cherney; Jie Liu; Karen Ellis James; James C Powers; Lindsay D Eltis; Michael N G James
Journal:  J Mol Biol       Date:  2006-12-02       Impact factor: 5.469

7.  Crystal structures of the main peptidase from the SARS coronavirus inhibited by a substrate-like aza-peptide epoxide.

Authors:  Ting-Wai Lee; Maia M Cherney; Carly Huitema; Jie Liu; Karen Ellis James; James C Powers; Lindsay D Eltis; Michael N G James
Journal:  J Mol Biol       Date:  2005-09-27       Impact factor: 5.469

8.  TBX2 represses CST6 resulting in uncontrolled legumain activity to sustain breast cancer proliferation: a novel cancer-selective target pathway with therapeutic opportunities.

Authors:  Zenobia C D'Costa; Catherine Higgins; Chee Wee Ong; Gareth W Irwin; David Boyle; Darragh G McArt; Karen McCloskey; Niamh E Buckley; Nyree T Crawford; Lalitha Thiagarajan; James T Murray; Richard D Kennedy; Karl A Mulligan; D Paul Harkin; David J J Waugh; Chris J Scott; Manuel Salto-Tellez; Richard Williams; Paul B Mullan
Journal:  Oncotarget       Date:  2014-03-30

9.  Knockdown of Legumain Suppresses Cervical Cancer Cell Migration and Invasion.

Authors:  Fei Meng; Wei Liu
Journal:  Oncol Res       Date:  2016-01-21       Impact factor: 5.574

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.